Study S002689

A Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise

ClinicalTrials.gov record

Registration

Registration: NCT06481085
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 324
Start: 2024-06-27
Primary completion: 2025-05-30
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HDM1002 50 mg; DRUG:HDM1002 100 mg; DRUG:HDM1002 200 mg; DRUG:HDM1002 400 mg; DRUG:HDM1002 200 mg BID; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change From Baseline in HbA1c at Week 12 [Baseline, Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.